Table 1.
Patient demographics separated by treatment condition.
| Variable | Level | Totala | Placebo | Sertraline | P-valueb |
|---|---|---|---|---|---|
| Age | All participants (74 placebo vs 70 sertraline) | 37.27 ± 13.71 | 36.38 ± 13.36 | 38.21 ± 14.10 | 0.42 |
| Sex | Female | 90 (62.50%) | 43 (47.78%) | 47 (52.22%) | 0.26 |
| Male | 54 (37.50%) | 31 (57.41%) | 23 (42.59%) | ||
| Race | American Indian/Alaska Native | 1 (0.69%) | 1 (100.00%) | 0 (0.00%) | 0.86 |
| Asian | 11 (7.64%) | 7 (63.64%) | 4 (36.36%) | ||
| Black or African American | 24 (16.67%) | 12 (50.00%) | 12 (50.00%) | ||
| Other | 9 (6.25%) | 5 (55.56%) | 4 (44.44%) | ||
| White | 99 (68.75%) | 49 (49.49%) | 50 (50.51%) | ||
| Hispanic | No | 120 (83.33%) | 61 (50.83%) | 59 (49.17%) | 0.77 |
| Yes | 24 (16.67%) | 13 (54.17%) | 11 (45.83%) | ||
| Site | CU | 46 (31.94%) | 22 (47.83%) | 24 (52.17%) | 0.76 |
| MG | 31 (21.53%) | 18 (58.06%) | 13 (41.94%) | ||
| TX | 43 (29.86%) | 23 (53.49%) | 20 (46.51%) | ||
| UM | 24 (16.67%) | 11 (45.83%) | 13 (54.17%) | ||
| MDD severityc | High | 74 (51.39%) | 36 (48.65%) | 38 (51.35%) | 0.50 |
| Low | 70 (48.61%) | 38 (54.29%) | 32 (45.71%) | ||
| MDD chronicityd | Chronic | 73 (50.69%) | 34 (46.58%) | 39 (53.42%) | 0.24 |
| Non chronic | 71 (49.31%) | 40 (56.34%) | 31 (43.66%) | ||
| Remitter | No | 91 (63.19%) | 49 (53.85%) | 42 (46.15%) | 0.44 |
| Yes | 53 (36.81%) | 25 (47.17%) | 28 (52.83%) | ||
| Week 0 HDRS score | All participants | 19.83 ± 3.59 | 19.55 ± 3.49 | 20.11 ± 3.70 | 0.35 |
| Week 8 HDRS score | All participants | − 8.38 ± 7.36 | − 7.62 ± 7.30 | − 9.17 ± 7.40 | 0.21 |
| % Change in HDRS score | All participants | − 42 ± 37 | − 40 ± 38 | − 45 ± 36 | 0.43 |
| Weighted FA between raphe and left amygdala | All participants | 0.42 ± 0.04 | 0.42 ± 0.03 | 0.43 ± 0.04 | 0.43 |
| Weighted FA between raphe and right amygdala | All participants | 0.43 ± 0.04 | 0.42 ± 0.04 | 0.43 ± 0.04 | 0.21 |
| Weighted FA between raphe and left hippocampus | All participants | 0.44 ± 0.05 | 0.43 ± 0.05 | 0.44 ± 0.05 | 0.22 |
| Weighted FA between raphe and right hippocampus | All participants | 0.45 ± 0.05 | 0.44 ± 0.05 | 0.46 ± 0.05 | 0.03e |
| Concurrent medication use | Yes | 78 (54.17%) | 39 (50%) | 39 (50%) | 0.74 |
| No | 66 (45.83%) | 35 (53.03%) | 31 (46.97%) |
a
Total displayed: mean ± SD for continuous variables; N (%) for categorical variables.
b
For continuous variables, p-values were calculated from Welch’s t-tests; for categorical variables, exact p-values were calculated from the Monte Carlo simulation. All p-values are calculated between placebo and sertraline groups.
c
Defined by HDRS ≥ 20 and QIDS-SR of ≥ 16.
d
Chronic is defined as > 2 years.
e
Not significant after multiple comparisons correction.